Zobrazeno 1 - 10
of 71
pro vyhledávání: '"Small-cell transformation"'
Autor:
Xi Ding, Min-xing Shi, Di Liu, Jing-xue Cao, Kai-xuan Zhang, Run-dong Zhang, Li-ping Zhang, Kai-xing Ai, Bo Su, Jie Zhang
Publikováno v:
Cell Communication and Signaling, Vol 22, Iss 1, Pp 1-16 (2024)
Abstract Objectives Histological transformation to small cell lung cancer (SCLC) has been identified as a mechanism of TKIs resistance in EGFR-mutant non-small cell lung cancer (NSCLC). We aim to explore the prevalence of transformation in EGFR-wildt
Externí odkaz:
https://doaj.org/article/dfbe49ee34af44d698240a23acfc7176
Publikováno v:
BMC Pulmonary Medicine, Vol 23, Iss 1, Pp 1-9 (2023)
Abstract Small cell transformation was one mechanism by which EGFR-mutation NSCLC acquired resistance after tyrosine kinase inhibitors (TKIs) treatment. A few reports of small cell transformation occurred in other oncogene-driven lung cancers. We fou
Externí odkaz:
https://doaj.org/article/fca9e12d383c48bd9119d669fbf27d45
Publikováno v:
Cancer Management and Research, Vol Volume 15, Pp 803-808 (2023)
Diming Wang,1,* Wei Ye,2,* Dongmei Chen,1 Qingming Shi,1 Dongchun Ma3 1Department of Oncology, Anhui Chest Hospital, Hefei, 230022, People’s Republic of China; 2Department of Pathology, Anhui Chest Hospital, Hefei, 230022, People’s Republ
Externí odkaz:
https://doaj.org/article/64fddfc48e124d769ebf7730eb790abf
Autor:
Umair Majeed, MD, Shenduo Li, MD, PhD, Karan Seegobin, MBBS, Aziza Nassar, MD, Rami Manochakian, MD, Yujie Zhao, MD, PhD, Yanyan Lou, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 7, Pp 100536- (2023)
ALK-EML4 fusion-positive lung adenocarcinomas (LUADs) are effectively treated with ALK tyrosine kinase inhibitors, but most patients eventually develop resistance to these drugs owing to ALK-dependent or independent mechanisms. Endothelial to mesench
Externí odkaz:
https://doaj.org/article/3c73aa028f9b41f9bb76d26b039694fb
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Thoracic Cancer, Vol 13, Iss 16, Pp 2394-2397 (2022)
Abstract Histological transformation from adenocarcinoma to small cell lung cancer (SCLC) occurs ~10% after acquired resistance to epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors. Transformed SCLC generally responds well to chemo
Externí odkaz:
https://doaj.org/article/b67b8f6eb8264877aef83485431dacf2
Autor:
Takuma Imakita, Kohei Fujita, Osamu Kanai, Misato Okamura, Masayuki Hashimoto, Koichi Nakatani, Satoru Sawai, Tadashi Mio
Publikováno v:
Thoracic Cancer, Vol 12, Iss 22, Pp 3062-3067 (2021)
Abstract In advanced lung cancer treatment, immunotherapy provides durable responses in some patients. However, other patients experience progressive disease and the resistance mechanisms to immunotherapy have yet been fully elucidated. Small cell tr
Externí odkaz:
https://doaj.org/article/898c28b337844146befb3de01718af18
Publikováno v:
Thoracic Cancer, Vol 12, Iss 22, Pp 3068-3071 (2021)
Abstract C‐ros oncogene 1 receptor tyrosine kinase (ROS1) rearrangement has been detected in patients with advanced non‐small cell lung cancer (NSCLC). Although ROS1 tyrosine kinase inhibitors (TKIs) provide a survival benefit for patients with R
Externí odkaz:
https://doaj.org/article/ed32ab372512427db583dba7cab3a7cf
Publikováno v:
Respiratory Medicine Case Reports, Vol 33, Iss , Pp 101440- (2021)
Small cell lung cancer (SCLC) transformation is a rare resistance mechanism to anaplastic lymphoma kinase-tyrosine kinase inhibitors (ALK-TKIs), for which cytotoxic chemotherapy is often initiated. However, no case has been reported so far in which t
Externí odkaz:
https://doaj.org/article/5234e6fe334149d0a42d82491e03f7b2